Cryo-EM Reveals Statin Triplets Force Open Muscle Calcium Channels

Key points

• UBC and University of Wisconsin-Madison researchers used cryo-electron microscopy to visualize statin interactions with the RyR1 protein in muscle cells.
• The study found that statins do not bind individually; instead, a triplet of molecules occupies a specific pocket in the protein.
• The first molecule binds while the channel is closed, increasing the likelihood of opening, while two additional molecules then hold the channel open.
• This sustained opening causes a continuous leak of calcium, which is the primary driver of muscle pain, weakness, and potential kidney failure in severe cases.
• The research focused primarily on atorvastatin but suggests similar mechanisms may apply to other statins in the drug family.
• These structural insights offer a target for modifying statin molecules to prevent muscle damage while maintaining cholesterol-lowering efficacy.

Background

Statins have been a cornerstone of cardiovascular care since their approval in the late 1980s, helping prevent millions of heart attacks and strokes. However, muscle-related side effects have long been a barrier to adherence, causing some patients to discontinue treatment. Previous studies in early 2026 had hinted at molecular triggers for these side effects, but this new research provides the first atomic-level view of how statins activate the RyR1 channel. The findings build on earlier discussions regarding statin safety and potential benefits, such as protection against depression, but focus specifically on resolving the physical side effects that limit patient compliance.

Why it matters

This discovery bridges a longstanding safety concern with a specific molecular process, offering a clear path for pharmaceutical development. By understanding exactly how statins interact with muscle proteins, scientists can design new versions of these drugs that avoid the harmful calcium leak. This could allow the 200 million global users of statins to continue their treatment without fear of severe side effects, ensuring they retain the life-saving benefits of cholesterol management. It also addresses the issue of patients quitting medication due to discomfort, which leaves them vulnerable to cardiovascular events.

What to watch

Researchers will use these structural insights to guide the development of safer statin variants. While the current findings are based on atorvastatin, further studies will determine if the same triplet-binding mechanism applies to other statins. Drug developers aim to modify the specific features of statin molecules that interfere with the RyR1 protein, creating treatments that are easier to tolerate. This could lead to new medications that maintain cholesterol control while significantly reducing the incidence of muscle pain and weakness, ultimately improving patient adherence and cardiovascular outcomes.